Atlas Trials

Turning Point Therapeutics, Inc.

9 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Turning Point Therapeutics, Inc.

RecordFirmDate
A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors (NCT05828303)Turning Point Therapeutics, Inc.2024-11-15
A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients (NCT05828277)Turning Point Therapeutics, Inc.2022-07-28
Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors (NCT05001516)Turning Point Therapeutics, Inc.2021-12-29
A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors (NCT05071183)Turning Point Therapeutics, Inc.2021-09-23
A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC (NCT04849273)Turning Point Therapeutics, Inc.2021-07-28
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations (NCT04094610)Turning Point Therapeutics, Inc.2020-03-12
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations (NCT04161391)Turning Point Therapeutics, Inc.2019-12-06
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (NCT03993873)Turning Point Therapeutics, Inc.2019-09-05

Track Turning Point Therapeutics, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.